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Abstract 
Despite advancements in lowering blood pressure, the best approach to lower it remains 
controversial due to the lack of information on the molecular basis of hypertension. We 
therefore performed plasma proteomics of plasma from patients with hypertension to 
identify molecular determinants detectable in these subjects but not in controls and vice 
versa. Plasma samples from hypertensive subjects (cases; n=118) and controls (n=85) 
from the “InGenious HyperCare” cohort were used for this study and performed mass 
spectrometric analysis. Using biostatistical methods, plasma peptides specific for 
hypertension were identified and a model was developed using least absolute shrinkage 
and selection operator logistic regression. The underlying peptides were identified and 
sequenced off-line using matrix assisted laser desorption ionization orbitrap mass 
spectrometry. By comparison of the molecular composition of the plasma samples, 27 
molecular determinants were identified differently expressed in cases from controls. 
70 % of the molecular determinants selected were found to occur less likely in 
hypertensive patients. In cross-validation, the overall R square was 0.434 and the area 
under the curve was 0.891 with 95% confidence interval 0.8482 to 0.9349, P<0.0001. 
The mean value of the cross-validated proteomic score of normotensive and 
hypertensive patients was found to be -2.007 ± 0.3568 and 3.383 ± 0.2643, P<0.0001 
respectively. The molecular determinants were successfully identified and the proteomic 
model developed shows an excellent discriminatory ability between hypertensives and 
notmotensives. The identified molecular determinants may be the starting point for 
further studies to clarify the molecular causes of hypertension. 
Key words: Hypertension, proteomics, blood pressure, anti-hypertensive drugs, 
modeling.  
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Introduction 
A recent survey on Global Burden of Disease1 has shown that, despite the availability of 
a number of effective blood pressure (BP) lowering drugs, the burden of disease caused 
by hypertension rather than decreasing, has continuously incremented worldwide. This 
indicates limitations of the diagnostic and therapeutic strategies so far implemented in 
managing hypertension and underscores the urgent need of new strategies for 
overcoming these limitations and reducing their consequences on public health. 
Under the diagnostic aspect, hypertension is identified on the simple basis of a number 
of BP measurements taken under standard conditions, but it is well known that BP is 
extremely variable and its measurements are scarcely reproducible.2  This has brought 
to a long lasting and continuing discussion on the preference to give to different BP 
assessment methods and settings: in the office by the doctor or the nurse, in the office 
with automatic equipment without the attendance of health professionals, at home or 
with 24-hour ambulatory monitoring. These different measurements also led to the 
definition of some categories or subtypes of hypertension such as “white coat 
hypertension” and “masked hypertension”.2 Though the use of these subtypes of 
hypertension has become very popular in the management of hypertension, there are no 
agreement yet on strategies for their management.3 Under the therapeutic aspect, a 
number of classes and compounds have been shown to effectively lower BP, thus 
reducing cardiovascular disease risk.4, 5 However, each of these classes is known to be 
effective only in a proportion of hypertensive patients and in the absence of proven 
predictors of their effect they are commonly prescribed by a trial and error strategy, and 
often in association in order to more easily and promptly achieve therapeutic goal.6  
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A more precise diagnosis and a better-targeted treatment of hypertension may result 
from understanding of the genetic and molecular basis of hypertension. While a number 
of genome-wide association studies have been performed on large population samples 
or cohorts of hypertensives, the molecular definition of hypertension is largely unknown.7  
However, with advancements in the proteomics field, the molecular determinants at a 
low concentration i.e. femtomolar range in a complex biological specimen like plasma 
can be analyzed using mass-spectrometry. Several plasma peptides have been reported 
as relevant in hypertension.8-11 Therefore, we investigated the differences in peptidic 
determinants profiles of plasma between normotensives and hypertensives by 
developing and applying a scoring system using a systems biology approach.  
In addition, new systems-medicine based model for hypertension could be established 
and validated based on the identified molecular determinants of hypertension. The use 
of these models for prognosis of hypertension might be of relevance, because it is still 
unclear when to best initiate the treatment of hypertension.6  
Methods 
Study population 
The “InGenious HyperCare” cohort (www.hypercare.eu) included individuals from 
families of probands with hypertension.12 Among first-degree relatives of probands, at 
least one was hypertensive and one from a different generation. Hypertension was 
defined as office systolic blood pressure (SBP) ≥140 mm Hg or office diastolic blood 
pressure (DBP) ≥90 mm Hg or the presence of antihypertensive treatment and 
hypertension diagnosis before the age of 50. From the families enrolled in 4 centers 
participating in InGenious HyperCare gave a written informed consent and approved by 
local research ethics committees at each participating centre and selected 282 
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individuals for the current study. This number was subsequently reduced to 203 because 
of the lack of satisfactory blood samples in 79 cases. Phenotypic characterization 
included: basic anthropometric and clinical information, office BP and organ damage 
assessment. Office BP was measured with the auscultatory method (at least two seated 
measurements were obtained in standard conditions). Organ damage was defined as 
the presence of any of the following: 1) left ventricular hypertrophy on echocardiography 
(left ventricular mass index, LVMI, indexed to body surface area) ≥115 g/m2 in males 
and ≥95 g/m2 in females; echocardiographic images from all centers were analyzed 
centrally at Istituto Auxologico Italiano, Milan; 2) presence of microalbuminuria 
(albumin/creatinine ratio ≥ 3.4 mg/mmol; samples analyzed by local laboratories); 3) 
presence of chronic kidney disease (estimated glomerular filtration ratio (eGFR) by 
CKD-EPI formula <60 ml/min/1.73 m2); 4) intima-media thickness of common carotid 
artery ≥0.9 mm on ultrasonography. 
Proteomic analysis 
Plasma proteomics was performed at the University Hospital RWTH Aachen, Institute for 
Molecular Cardiovascular Research (IMCAR) (Aachen, Germany) by using liquid 
chromatography-electrospray ionization-mass-spectrometry (LC-ESI-MS), matrix-
assisted-laser-desorption ionization-time of flight-mass-spectrometry (MALDI-TOF-MS), 
MALDI LTQ Orbitrap XL and gas chromatography mass spectrometry (GC-MS). Figure 
1A shows the workflow for proteomic analysis.  
Statistical Methods 
For statistical analysis we used Statistical Analysis System (SAS) software version 9.3 
(SAS Institute, USA), Graph Pad Prism 6.0 software and R version 3.2.4.13 Generally, 
continuous variables are reported as means and standard deviation (SDs) or median 
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and inter quartile range in case of non-normally distributed data and compared between 
groups using unpaired t-tests. Categorical variables are presented as percentages and 
frequencies. For plasma proteomic model development, we employed LASSO logistic 
and ridge regressions, flow chart of biostatistical analysis is shown in Figure 2A. More 
details about sample preparation and development of the model can be found in 
supplementary information of the manuscript. 
In order to assess whether the cross-validated proteomic score was associated with 
clinical variables, we performed statistical tests (unpaired t-test or Mann-Whitney U test; 
Pearson’s or Spearman’s correlation) as well as multivariable logistic regression with 
hypertension status as binomial outcome and the cross-validated proteomic score, age, 
sex, BMI, diabetes, use of renin-angiotensin-aldosterone antagonists, SBP and DBP, 
heart rate and the presence of organ damage as explanatory variables. Additionally, 
multiple regression analysis with proteomic score as dependent variable and 
hypertension status, age, sex, BMI, diabetes, use of renin-angiotensin-aldosterone 
antagonists, SBP and DBP, heart rate and the presence of organ damage as predictor 
variables. We also compared the proteomic score according to hypertension control and 
the use of antihypertensive medication in the analysis of variance (ANOVA). 
  
RESULTS 
Characteristics of subjects  
The study population was divided into 118 hypertensives (cases) and 85 controls 
according to the criteria described above. The characteristics of patients suffering from 
hypertension and controls are shown in Table 1. The percentage of males was 45.9% 
and 50.0% in controls and cases, respectively. Patients suffering from hypertension had 
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a SBP/DBP of 150.2±21.5/88.6±12.1 mm Hg compared to 131.0±14.9/79.7±9.9 mm Hg 
in the control group. The mean age, weight, body mass index and body surface area 
were found to be significantly higher in hypertensive patients as well (Table 1). Nine 
patients and three controls were diabetic. Coronary disease and myocardial infarction 
were diagnosed in 9 and 6 patients respectively, but not in controls. Furthermore, 
creatinine was higher and eGFR levels were significantly lower in hypertensive cases vs. 
normotensive subjects respectively. Significant differences were observed in glycemia 
and triglyceride levels and no differences were observed in lipid levels except for 
triglycerides. As expected cases had higher prevalence of organ damage overall as well 
as of each evaluated marker separately (Table 1). 
Plasma proteomics 
To identify the molecular determinants, we employed a plasma peptidomic approach by 
using mass-spectrometry. A characteristic total ion chromatogram (TIC) of a case and a 
control is shown in Figure 1B and Figure 1C respectively, showing the summation of 
the intensities of all mass signals detected as a function of LC retention time within a 
single run. The TICs of a case and a control were slightly different from each other. A 
corresponding representative average mass spectrum of a case and a control is 
depicted in Figure 1D and Figure 1E, respectively. 
Biostatistical analysis  
The raw data obtained from the mass-spectrometry were normalized using the internal 
standard. Then, an algorithm for peak picking was employed to combine all ions that 
derive from the same compound, thus considerably reducing the size and complexity of 
the dataset to be analyzed. Further, to simplify the data for statistical analysis, 
chromatograms were transferred into buckets with the information on intensity, m/z and 
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the retention time of the each molecular feature. Overall, 12,926 molecular features 
were detected, of which 403 features had 16.7% or more non-zero intensity values 
across all plasma samples. From these 403 features, 27 features were selected as 
predictive for the case-control status using LASSO logistic regression. Regression 
coefficients for the D (average non-zero vs. zero intensity) and X components (given 
non-zero intensity, log odds per tenfold increase of intensity) of selected peptides were 
ranked and depicted. The resulting proteomic model had a global p-value < 0.01 and an 
overall R2 of 0.434. We found that down-regulation of 19 features and up-regulation of 8 
features was associated with a higher probability of hypertension (Table 2). No 
additional molecular determinants were identified if model development was repeated 
after removing the features selected in the first run. 
A proteomic score was calculated for each subject by cross-validation by leaving out a 
subject. Figure 2B depicts the proteomic scores as boxplots. The scores of 
hypertensive patients were higher when compared to the control subjects, with the mean 
values of the predictor score being 3.383 ± 0.2643 and -2.007 ± 0.3568, p<0.0001 
respectively. Furthermore, the diagnostic power of these 27 molecular determinants was 
determined by receiver operating characteristic (ROC) analysis (sensitivity vs. 1-
specificity, Figure 2C). The concordance index (area under the ROC) was 0.891 (95% 
confidence interval 0.8482 to 0.9349, P<0.0001).  
Clinical correlates of the proteomic score 
In univariable analyses the proteomic score correlated with age (r=0.43), BMI (r=0.22), 
SBP (r=0.29), DBP (r=0.16), creatinine (r=0.18), eGFR (r=-0.27), LVMI (corrected for 
body surface area – r=0.25 or for height2.7 – r=0.28), IMT (r=0.24), urinary 
albumin/creatinine ratio (r=0.28) and the number of antihypertensive drugs (r=0.49). It 
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was higher in subjects with history of coronary disease (3.91±3.2 vs. 1.00±4.0, p=0.034) 
or myocardial infarction (5.08±2.7 vs. 1.01±4.0, p=0.015), in those with any organ 
damage (2.19±4.0 vs. 0.14±3.5, p=0.013), and a tendency toward higher values was 
also observed in males (1.62±4.0 vs. 0.67±4.1, p=0.095) and in diabetic subjects 
(3.23±4.34 vs. 0.96±4.0, p=0.058).  
In multiple logistic regression analysis the association with the presence of hypertension 
was significant for the proteomic score, age and presence of organ damage (Table 3), 
with model R2 = 0.65. A further multiple regression analysis was done with proteomic 
score as the dependent variable. In this model, the presence of hypertension was the 
only strong independent predictor, with BMI also showing borderline significant 
association; age was no longer significant in this model. The total predictive capacity of 
the model was R2 =0.42; Table 4). Considering the subgroups of cases we found no 
significant difference in the proteomic score between treated and untreated (3.58±2.9 vs. 
2.22±2.4, p=0.07), between uncontrolled and controlled individuals (3.2±3.0 vs. 3.80±2.3, 
p=0.34), between those with or without organ damage (2.96±3.4 vs. 3.51±2.7, p=0.38) 
and between those with or without any complication of hypertension (organ damage, 
diabetes, history of CVD) (3.30±3.2 vs. 3.38±2.7, p=0.90).  
Identification of selected features and associated pathways  
The 27 selected molecular determinants were identified using MALDI-TOF-TOF-MS and 
verified with LTQ-Orbitrap MS. Figure 2D represents a characteristic mass-spectrum of 
a plasma sample with indication of a molecular feature with m/z 736.9. Its respective 
fragmentation spectra is shown in Figure 2E. The signal at m/z 736.9 was found to be a 
fragment of phosphoinositide 3-kinase regulator (PI3KR1). The other features integrated 
in our final predictive hypertension model were identified as fragments of humanin (MT-
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RNR2), ancotamin 10 (ANO10), NIK related protein kinase (NRK), mannose-6-phospho 
isomerase (MPI), tryptophan, erythrocyte membrane glycopeptide, transcription factor 
Dp-2 (TFDP2), pleckstrin homology domain-containing family (PLEKHO1), cardiac 
phospholamban (PLN), osteocalcin (BGLAP) or sarcolipin (SLN), ras-related protein 
Rab-13 (RAB13), protein prune homolog (PRUNE), nexilin (NEXN) and paladin (PALLD) 
proteins. One of the features was identified as tryptophan. The whole list of identified 
molecular determinants is presented in Table S1 of supplementary data. To get an 
insight into pathophysiological role of these molecular determinants, we did literature 
mining. The functions and related pathways associated with the molecular determinants 
were summarized in Table S1. The pathway information was extracted from Gene 
Cards, and reported only the pathways, which had a score above 0.5. For PI3KR1, 
super pathways were reported, as this protein is associated with many pathways. In 
order to gain mechanistic insight into the pathophysiology of hypertension, KEGG and 
GO database searches were performed based on the 27 molecular determinants 
integrated in our proteomic model (supplementary data).  
Discussion 
In the present study, a comparative analysis of hypertensive patients vs. controls was 
performed on molecular level using systems biology approach. We developed a 
proteomic model based on the differences in peptidic profiles of plasma using 27 
molecular determinants. The model shows an excellent discriminatory ability. Moreover, 
stability of the model is suggested since no additional molecular determinants could be 
detected if the originally selected determinants were omitted from model development. 
However, the low drop in R2 values of the individual components of the combined 
proteomic score show that it is not a single molecular determinant that dominates the 
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model but rather the combination of many different molecular properties that is 
responsible for the superior performance of the model. 
Using mass-spectrometry, we were able to identify 18 from the 27 molecular 
determinants selected, whereas the remaining 9 features remain currently unknown. 
Among the identified molecular determinants, 66.6% have negative β10fold and βnonzero 
values, implying that they act as protective molecular determinants. Three proteins 
namely, humanin, osteocalcin and sarcolipin were included twice in the model with 
different signature sequence.  
The peptidomic changes found in hypertensive patients may have several reasons: first 
these changes may be related to the pathogenesis of hypertension. We may assume 
such a relationship for those peptidic molecular determinants, which are known to 
mediate vasoconstriction or vascular smooth muscle cell growth.14, 15 Second, the 
change in the peptidome of hypertensives may be a consequence of hypertension. This 
relationship may be assumed for peptides, which are secreted from myocardial cells. 
Increased amounts of these peptides may be secreted due to left ventricular 
hypertrophy.16-18 Third, peptidomic changes may be the consequence of 
antihypertensive treatment. It is conceivable that especially substances blocking 
neurohumoral transmission, such as ACE inhibitors or beta-blockers, can induce counter 
regulatory processes.19 These may also include the secretion of vasoregulatory peptides. 
It is beyond the scope of this study to review the functions of the peptides associated 
proteins extensively but these are briefly explained in Table S1.  We identified peptide 
fragments of sarcolipin and phospholamban, which are proteins involved in cellular 
calcium metabolism and vessel contraction.20, 21 Furthermore, we identified peptide 
fragments originating from humanin and osteocalcin proteins involved in 
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atherogenesis,18, 22, 23 proteins involved in cytoskeletal organization and regulation 
(pleckstrin, palladin and nexilin), but also cellular proliferation is affected by protein 
prune homolog, NIK related protein kinase, transcription factor Dp-2.24-26 Lastly, 
angiogenesis is a target of ras-related protein Rab-13.27 Mannose phosphate isomerase 
is a ubiquitous enzyme, which, however, might be involved in the mannosylation of 
prorenin, thus facilitating its cellular uptake and hence angiotensinogen splitting.28  
From the various physiological effects of these peptides it is difficult to decide whether 
changes in these peptides are related to the cause or the consequence of hypertension, 
or which are related to causes and which to consequences. On the one hand, altered 
angiogenesis, contraction or cytoskeleton may be pathogenetically important, but on the 
other hand hypertension may induce both left ventricular and vascular hypertrophy and, 
as a further consequence, also changes in peptidic messengers regulating 
cardiovascular structure and function. The proteomic approach focus on the 
identification of potential bioactive substances therefore, each of the substances 
identified and their combination in the current study should be characterized in in vivo 
models in future. Furthermore, future research has to be performed to determine if some 
of these molecules are present before the development of clinically detectable 
hypertension.  
Multiple regression analyses revealed that hypertension was the strongest predictor of 
the proteomic score and this association was independent of age, sex, antihypertensive 
treatment, comorbidities or organ damage. This suggests that this score, when elevated, 
may indeed reflect the alterations of regulatory mechanisms leading to hypertension 
development or very early cardiac and vascular changes, rather than being the 
consequence of advanced hypertension. In this respect, the population of subjects 
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provided by the InGenious HyperCare cohort was particularly suitable for exploring 
mechanisms of hypertension, as hypertension was defined as high blood pressure 
diagnosed before age 50 years, thus excluding hypertension initiated at an older age 
when elevated blood pressure is largely dependent on large artery stiffening.  
Several previous attempts have been made to elucidate hypertension-specific changes 
in the plasma peptidome. Araki et al.29 studied the plasma peptidome from hypertensive 
pregnant women. In this study, 23 peptide peaks differed significantly between 
hypertensive pregnant women and healthy controls, with 11 peptides showing lower 
concentrations and 12 peptides showing higher concentrations in hypertension. Seven 
peptides were proteolytic fragments of higher molecular plasma proteins, suggesting an 
enhanced activity of proteolytic enzymes. Myers et al.30 similarly performed mass 
spectrometric studies to identify proteins or peptides as markers of preeclampsia, which 
is a hypertensive pregnancy complication. They identified other markers than the 
aforementioned study, possibly due to methodological reasons. Gebhard et al.31 showed 
that proteomic changes might also be the consequence of hypertension. They found that 
Ang II induced the biosynthesis of several cytoskeletal proteins in platelets. Other 
proteins were identified as pleckstrin and RAS-related protein Rab-11A. Similar peptides 
were also identified in the present study, suggesting that some of the changes described 
in our study may indeed be the consequence of high BP. Matafora et al.32 followed a 
similar approach to determine changes in the urinary proteome specific for hypertension. 
They also identified proteomic changes, which were most likely markers of renal 
hypertensive damage. 
Several limitations of the present study have to be mentioned: First, as detailed above, 
no conclusions as to the etiology of hypertension can be made from these data. A 
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causal relationship cannot be inferred from a statistical association, and influences from 
antihypertensive treatment may contribute to the peptidomic changes. Nevertheless, the 
present methodology may open up a new approach to define factors in the etiology of 
primary hypertension. Therefore, this study may stimulate new questions, which can be 
answered by studying selected groups of hypertensive patients and prehypertensive 
patients, e.g. those still untreated or those without vs. with left ventricular hypertrophy. 
Moreover, a study on secondary hypertensives may help understanding which 
peptidomic changes are rather a consequence than a cause of primary hypertension. 
Also, a study with longer follow-up may enable to identify molecular determinants and an 
associated proteomic-scoring model to predict the development of a comorbid disease 
status (e.g. CVD, diabetes) in hypertensive patients at later time points. 
In conclusion, plasma analysis by mass spectrometry enabled us to short list a series of 
molecules linked to hypertensive patho-biology. Our findings demonstrated that with 
appropriate technologies plasma could be used as a source for the identification of 
molecular determinants of hypertension. Since hypertension is noted as one of the major 
risk factors of CVD, a similar approach could be used in subsequent studies to improve 
the screening and diagnosis of patients that are at a risk for CVD. 
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Perspectives 
In this case-control study, we investigated the differences in peptidic profiles of plasma 
from normotensives and hypertensives by developing and applying a scoring system 
using a systems biology approach. In addition, new systems-medicine based model for 
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hypertension is established and has an excellent discriminatory ability based on the 
identified molecular determinants of hypertension. In future, the substances identified in 
this study have to be validated as mediators of hypertension in animal studies and 
bioassays.  
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Novelty and Significance 
What Is New?  
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A more precise diagnosis and a better-targeted treatment of hypertension may result 
from understanding of the genetic and molecular basis of hypertension. Therefore, we 
analyzed plasma proteomic phenotypes of hypertension by robust proteo-biostatistic 
integrated approach with the “InGeniousHypercare” cohort, a cohort of hypertensive 
probands. 
 
What Is Relevant? 
By plasma peptidomic comparative analysis we identified the molecular features 
significantly different in hypertensive and control subjects. These features provide new 
insights in the genesis and progression of hypertension and may provide new targets for 
the treatment of hypertension. 
Summary 
In the current systems medicine based study we were able to identify significant 
differently expressed peptides and proteins in subjects with hypertension and control 
subjects. These molecular features will be useful to clarify the molecular causes of 
hypertension and to predict the development of hypertension and of associated 
cardiovascular events in the future. 
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Figure legends 
Figure 1: Sample preprocessing and mass spectrometric analysis 
(A)  Outline of the steps followed in sample preparation for mass spectrometer 
and processing the data for statistical analysis 
(B)  Characteristic total ion chromatogram of a sample from the case subgroup 
(C)  Characteristic total ion chromatogram of a sample from the control subgroup 
(D)  Corresponding average mass spectrum of a sample from the case subgroup 
(E)  Corresponding average mass spectrum of a sample from the control 
subgroup 
 
Figure 2: Development of a predictor model and identification of peptides that 
distinguish the hypertensive and normotensive subjects 
(A)  Schematic representation of steps involved in the development of a predictor 
model for hypertension 
(B)  Box-plot of a cross-validated plasma proteomics model for hypertension, 
p<0.0001 
(C)  ROC curve of the cross-validated plasma proteomics model with an area 
under curve of 0.891 (95% confidence interval 0.8482 to 0.9349. P<0.0001) 
(D) Representative mass spectrum of the selected molecular feature with m/z of 
736.9 
(E) Representative fragmentation spectra of the selected molecular feature with 
m/z of 736.9 
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Table 1. Baseline characteristics of InGenious HyperCare cohort 
Variable Controls (n=85) 
Cases 
(n=118) 
P-value 
Demographics       
  Male, n (%) 39 (45.9) 59 (50.0) n.s 
  Age (years)* 34 (27-45) 53 (48-60) < 0.0001 
Physical examination       
  Height (cm) 170.7 ± 9.8 169.0 ± 9.1 n.s 
  Weight (kg) 77.3 ± 13.7 86.9 ± 16.3 < 0.0004 
  Body mass index (kg/m2) 26.6 ± 4.4 30.4 ± 4.9 < 0.0001 
  Body surface area (m2) 1.9 ± 0.2 2.0 ± 0.2 0.0222 
  SBP (mmHg)* 133.0 (123.0-138.0)  148.0 (135.8-162.0) < 0.0001 
  DBP (mmHg)* 79.0 (73.0-86.0) 88.0 (81.0, 95.3) < 0.0001 
  Heart rate (bpm) 70.1 ± 9.9 68.9 ± 11.0 n.s 
Clinical history       
  Diabetes, n (%) 3 (3.5) 9 (7.6) n.s 
  Coronary disease, n (%) 0 9 (7.6) 0.0066 
  Myocardial infarction, n (%) 0 6 (5.0) 0.0365 
Medications       
  Antihypertensive treatment, n 
(%) 
8 (9.4) 111 (94.1) <0.0001 
  Use of RAAS blocker, n (%) 5 (5.6) 82 (69.5) <0.0001 
Biochemical data       
  Creatinine (µmol/L) 72.9 ± 10.9 79.3 ± 26.7 0.0392 
  eGFR (ml/min) 93.5 ± 19.7 80.3 ± 16.7 < 0.0001 
  Glycemia (mmol/L)* 4.8 (4.5-5.3) 5.3 (4.8-5.9) 0.0002 
  Total cholesterol (mmol/L) 5.2 ± 1.1 5.2 ± 1.2 n.s 
  HDL (mmol/L) 1.4 ± 0.3 1.4 ± 0.7 n.s 
  LDL (mmol/L) 3.2 ± 0.9 3.0 ± 1.1 n.s 
  Triglyceride (mmol/L) 1.5 ± 1.4 1.8 ± 0.9 0.0006 
Organ damage       
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  Left ventricular mass index 
(g/m2) 
80.9 ± 1.6 92.3 ± 1.8 < 0.0001 
  Left ventricular mass index 
(g/m2.7) 
36.3 ± 0.9 44.2 ± 1.0 < 0.0001 
  Left ventricular hypertrophy, 
N(%)  
8 (9.5) 26 (22.6) 0.0114 
  Albumin/creatinine ratio 
(mg/mmol) * 
0.48 (0.00-0.89) 1.15 (0.56-2.50) 0.0001 
  Microalbuminuria, N(%) 1 (2.3) 11 (20.0) 0.0062 
  Chronic kidney disease, N(%) 3 (3.6) 10 (8.9) n.s. 
  Common carotid IMT (mm) 0.58 ± 0.12 0.68 ± 0.14 < 0.0001 
  IMT ≥0.9 mm, N(%) 3 (3.5) 11 (9.5) 0.0845 
  Any organ damage, N(%) 4 (4.7) 27 (22.9) 0.0002 
* - median and interquartile range DBP=diastolic blood pressure, eGFR=estimated 
glomerular filtration rate, HDL=high density lipoprotein, IMT=intima-media thickness, 
LDL=low density lipoprotein, RAAS=renin angiotensin aldosterone system, SBP=systolic 
blood pressure, n.s=not significant. 
 
Table 2. Identified features and their coefficients  
m/z 
β10fold 
βnonzero Prnonzero 
Dynamic range Drop in R2 
Down-regulated in hypertensive patients  
344.21 -0.9862 -1.2175 35 4.7940 -0.0006 
811.37 -0.7529 -0.9328 35 1.6952 0.0023 
358.23 -0.6049 -0.7483 41 2.7697 0.0032 
1043.44 -0.4497 -0.7334 42 3.6804 0.0143 
549.78 -0.6083 -0.7227 45 4.8103 0.0027 
148.42 -0.499 -0.7150 54 6.0856 0.0354 
317.24 -0.4611 -0.6449 54 3.0719 0.0002 
173.30 -0.4507 -0.5295 58 4.9854 0.0003 
346.02 -0.3984 -0.5177 58 3.9033 0.0029 
167.27 -0.4534 -0.4719 59 3.3400 0.0008 
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803.25 -0.3249 -0.4650 61 10.1504 0.0344 
1003.47 -0.3027 -0.4608 63 3.4437 0.0085 
327.22 -0.4421 -0.4482 63 3.6884 0.0011 
149.59 -0.4645 -0.4399 64 5.2870 0.0128 
187.58 -0.4246 -0.4189 65 6.1546 0.0065 
736.91 -0.3727 -0.3334 68 4.0306 0.0020 
359.21 -0.1891 -0.2553 68 2.3112 0.0088 
647.21 -0.1281 -0.2045 77 3.5131 0.0041 
266.09 -0.1045 -0.0993 90 3.9237 -0.0003 
Upregulated in hypertensive patients   
266.16 0.1246 0.1655 93 2.3868 0.0003 
302.22 0.1856 0.2232 114 4.9577 0.0016 
355.02 0.3620 0.3860 126 3.8948 0.0054 
274.15 0.4822 0.5021 162 5.3861 0.0007 
909.49 0.3429 0.5549 168 7.2189 0.0073 
169.59 0.5351 0.9185 177 7.1732 0.0118 
852.52 0.8124 1.3102 182 7.4410 0.0095 
268.23 0.6820 1.3813 194 5.6759 0.0025 
β10fold and βnonzero describe the logistic regression coefficients (log odds increase for 
hypertension) per 10fold increase of an intensity value and for comparing average non-
zero intensity to a zero intensity value, respectively. Prnonzero denotes the proportion of 
nonzero values across the 203 samples. The dynamic range of intensity values refers to 
range on the log2 scale. i.e. how often the lowest nonzero intensity value has to be 
‘doubled’ in order to be equal to the highest nonzero intensity value. Drop in R2 
describes the importance of each predictor in terms of drop in R2 if the variable is 
remove 
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Table 3. Logistic regression model linking the presence of hypertension with the 
proteomic score and major clinical variables 
Variable OR (95% CI) P-value 
Proteomic score 2.02 (1.58-2.57) <0.0001 
Age (per 10 years) 3.99 (2.25-7.07) <0.0001 
BMI 1.10 (0.98-1.23) 0.0915 
Sex (Male vs Female) 1.66 (0.55-5.00) 0.3697 
Organ Damage 13.68 (1.83-102.09) 0.0107 
HR (per 10 bpm) 1.29 (0.70-2.38) 0.4148 
BMI=body mass index, HR=heart rate. 
 
 
 
Table 4. Logistic regression model linking the proteomic score with hypertension 
and major clinical variables 
Variables Beta SE of Beta P-value 
Sex -0.181085 0.091495 0.051280 
Age -0.036913 0.134954 0.785167 
hypertension -0.624723 0.133414 0.000012 
BMI -0.221700 0.106824 0.041206 
Organ Damage 0.039269 0.134910 0.771753 
eGFR -0.086320 0.101515 0.397721 
UACR 0.163188 0.097648 0.098642 
LVMI (Height) 0.075009 0.135947 0.582677 
Glycemia -0.105117 0.088147 0.236624 
BMI=body mass index, eGFR=estimated glomerular filtration rate, LVMI=left ventricular 
mass index, SE=standard error, UACR=urinary albumin-creatinine ratio. 
 
 


